First Header Logo Second Header Logo

Connection

Michael Rocco to Glomerular Filtration Rate

This is a "connection" page, showing publications Michael Rocco has written about Glomerular Filtration Rate.
Connection Strength

1.442
  1. Rocco MV, Chapman A, Chertow GM, Cohen D, Chen J, Cutler JA, Diamond MJ, Freedman BI, Hawfield A, Judd E, Killeen AA, Kirchner K, Lewis CE, Pajewski NM, Wall BM, Yee J. Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration Definitions. Am J Nephrol. 2016; 44(2):130-40.
    View in: PubMed
    Score: 0.533
  2. Potok OA, Ix JH, Shlipak MG, Katz R, Hawfield AT, Rocco MV, Ambrosius WT, Cho ME, Pajewski NM, Rastogi A, Rifkin DE. The Difference Between Cystatin C- and Creatinine-Based Estimated GFR and Associations With Frailty and Adverse Outcomes: A Cohort Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Kidney Dis. 2020 12; 76(6):765-774.
    View in: PubMed
    Score: 0.175
  3. Malhotra R, Katz R, Jotwani V, Ambrosius WT, Raphael KL, Haley W, Rastogi A, Cheung AK, Freedman BI, Punzi H, Rocco MV, Ix JH, Shlipak MG. Urine Markers of Kidney Tubule Cell Injury and Kidney Function Decline in SPRINT Trial Participants with CKD. Clin J Am Soc Nephrol. 2020 03 06; 15(3):349-358.
    View in: PubMed
    Score: 0.170
  4. Beddhu S, Shen J, Cheung AK, Kimmel PL, Chertow GM, Wei G, Boucher RE, Chonchol M, Arman F, Campbell RC, Contreras G, Dwyer JP, Freedman BI, Ix JH, Kirchner K, Papademetriou V, Pisoni R, Rocco MV, Whelton PK, Greene T. Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT. J Am Soc Nephrol. 2019 08; 30(8):1523-1533.
    View in: PubMed
    Score: 0.163
  5. Kramer H, Berns JS, Choi MJ, Martin K, Rocco MV. 25-Hydroxyvitamin D testing and supplementation in CKD: an NKF-KDOQI controversies report. Am J Kidney Dis. 2014 Oct; 64(4):499-509.
    View in: PubMed
    Score: 0.116
  6. Bullen AL, Katz R, Lee AK, Anderson CAM, Cheung AK, Garimella PS, Jotwani V, Haley WE, Ishani A, Lash JP, Neyra JA, Punzi H, Rastogi A, Riessen E, Malhotra R, Parikh CR, Rocco MV, Wall BM, Bhatt UY, Shlipak MG, Ix JH, Estrella MM. The SPRINT trial suggests that markers of tubule cell function in the urine associate with risk of subsequent acute kidney injury while injury markers elevate after the injury. Kidney Int. 2019 08; 96(2):470-479.
    View in: PubMed
    Score: 0.040
  7. Weir MR, Lakkis JI, Jaar B, Rocco MV, Choi MJ, Kramer HJ, Ku E. Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report. Am J Kidney Dis. 2018 12; 72(6):873-884.
    View in: PubMed
    Score: 0.038
  8. Beddhu S, Rocco MV, Toto R, Craven TE, Greene T, Bhatt U, Cheung AK, Cohen D, Freedman BI, Hawfield AT, Killeen AA, Kimmel PL, Lash J, Papademetriou V, Rahman M, Rastogi A, Servilla K, Townsend RR, Wall B, Whelton PK. Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney Disease: A Secondary Analysis of a Randomized Trial. Ann Intern Med. 2017 Sep 19; 167(6):375-383.
    View in: PubMed
    Score: 0.036
  9. Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, Cushman WC, Hawfield AT, Johnson KC, Lewis CE, Oparil S, Rocco MV, Sink KM, Whelton PK, Wright JT, Basile J, Beddhu S, Bhatt U, Chang TI, Chertow GM, Chonchol M, Freedman BI, Haley W, Ix JH, Katz LA, Killeen AA, Papademetriou V, Ricardo AC, Servilla K, Wall B, Wolfgram D, Yee J. Effects of Intensive BP Control in CKD. J Am Soc Nephrol. 2017 Sep; 28(9):2812-2823.
    View in: PubMed
    Score: 0.035
  10. Freedman BI, Gadegbeku CA, Bryan RN, Palmer ND, Hicks PJ, Ma L, Rocco MV, Smith SC, Xu J, Whitlow CT, Wagner BC, Langefeld CD, Hawfield AT, Bates JT, Lerner AJ, Raj DS, Sadaghiani MS, Toto RD, Wright JT, Bowden DW, Williamson JD, Sink KM, Maldjian JA, Pajewski NM, Divers J. APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume. Kidney Int. 2016 08; 90(2):440-449.
    View in: PubMed
    Score: 0.033
  11. Divers J, Palmer ND, Lu L, Langefeld CD, Rocco MV, Hicks PJ, Murea M, Ma L, Bowden DW, Freedman BI. Gene-gene interactions in APOL1-associated nephropathy. Nephrol Dial Transplant. 2014 Mar; 29(3):587-94.
    View in: PubMed
    Score: 0.027
  12. Divers J, Núñez M, High KP, Murea M, Rocco MV, Ma L, Bowden DW, Hicks PJ, Spainhour M, Ornelles DA, Kleiboeker SB, Duncan K, Langefeld CD, Turner J, Freedman BI. JC polyoma virus interacts with APOL1 in African Americans with nondiabetic nephropathy. Kidney Int. 2013 Dec; 84(6):1207-13.
    View in: PubMed
    Score: 0.027
  13. Freedman BI, Langefeld CD, Turner J, Núñez M, High KP, Spainhour M, Hicks PJ, Bowden DW, Reeves-Daniel AM, Murea M, Rocco MV, Divers J. Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease. Kidney Int. 2012 Oct; 82(7):805-11.
    View in: PubMed
    Score: 0.025
  14. Freedman BI, Langefeld CD, Murea M, Ma L, Otvos JD, Turner J, Antinozzi PA, Divers J, Hicks PJ, Bowden DW, Rocco MV, Parks JS. Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans. Nephrol Dial Transplant. 2011 Nov; 26(11):3805-10.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.